CHINA. It’s the world’s second-largest national pharmaceutical market and also the biggest emerging market for pharmaceuticals. The China Food and Drug Administration (CFDA) has been busy implementing regulatory reforms and focused on prioritizing drug innovation and world class clinical trial standards. Simultaneously, China has been focused on patent law reform, making it a much more patent-friendly jurisdiction, benefiting innovators worldwide. Based on these facts alone it should be a no-brainer for your company to enter this market. Right? The question you always hear however is whether the opportunity justifies the (perceived) risks of doing business in China, particularly around the preserving the value of and protecting your intellectual property in China.

Learn all about the notable changes to China's patent laws from a China-based IP expert followed by an engaging panel discussion on strategies for protecting and maximizing the value of your intellectual property assets in China.

Notable changes to China’s Patent Law we will cover include:

Other topics that will be address will include the following: